OFIX — Stock Film
STOCK FILMSCENE 1/11OFIX · $10.01
Stock Expert AI presents
OFIX
Orthofix Medical Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Orthofix Medical Inc. A quick introduction.

On the stock market since 1992, it operates in the world of health and science. It has 1,605 employees. Now — the numbers.

on the stock market since 1992
1,605 employees
$491.9M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 15% a year over the last 4 years. Red columns mark years that ended in a loss.

$464.5M
2021
$460.7M
2022
$746.6M
2023
$799.5M
2024
$822.3M
2025
In the vault right now:
$0
DEBT: $229.3M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
77
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
32
very weak

Clearly below the class average.

VALUATION
77
strong

Clearly above the class average — a step short of the very top.

GROWTH
50
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
29
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark0/10
THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 77% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 21% a year on average.

2
THE BRIGHT SIDE · 2/3
Sales are holding up

The company sells $822.3M a year; the problem isn’t sales — it’s costs running above that number.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 41 buys and 22 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
The losses continue

A loss of $92.2M against $822.3M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, OFIX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: OFIX has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film